Jeff. Thank you,
energizing serve. that plan moving with were the of first on then three phase a And an had last business, accelerate call we out we then that laid focusing my into I that investors on phase first spring, So and phases a at the in to really markets time leading it.
bit within Apollo place as that a provides first done little of we've So energized during premium a over it Slide little XX And our a people a of delivering phase, scorecard, know were high on a very commitments. that I year. on how
how So done. we've let's talk about
was strategic for study milestones, of FDA was merit journal. MERIT going a U.S. and to revisions. study been were endoscopic grow. fundamental exceptional Those represented authorization we that transformation. we've field of product The to in of said July. that publication be number continues endobariatrics pursuing important the tier ESG now for We an Lancet We a delivers in terms that were In and was in and step a product X-Tack then in the adoption that It forward procedure we also that July. clinical the the said portfolio all the value. is And granted two undergoing worthy in in our while, published the the that top new in said we believed financial
in our that XX%. QX announced took quarter reason in that quarter as growth we just If XXXX the is to over and and I period growth the it before you right that the compare our CEO, was compare of
towards Jeff becoming a Apollo flow while, pathway break-even. a the have And So and sheet balance we company. is strengthened rapidly cash clear the all growth very as mentioned
at the President the Medical University of Executive on we've of the in directors. the to I Sharon revitalizing added have additions. particularly levels, some period short and time. board, want the been Senior the board Jeannette but already again Bankes, our who's to organization all significant we've highlight at and of addition, former Chicago the value Sharon leadership O'Keefe, tremendous and In Jeanette Alcon, additions of of made recent a Center
building board our Just an fresh very them. already been to perspectives new functional in thrilled strong capabilities in key we organization. highlighted have to on and team and mass the also adding are expand hiring on critical We've economics to the slide And do as the and we we so. few in continue in the our R&D marketing. best we're and of team industry in reimbursement health some in sales a and We've
just entirely is a a company over different ago. we year a And than so little were Apollo
you attention I'm the early I opportunities opportunity, see about suturing accelerate expanding turn phase. new talk very channel, today to either And access and that to them and OverStitch pleased our so that phase, four endobariatric now the then slide, are significant drive them to that NXT the outside on earlier, U.S. we commercial will referenced with expansion the pursuing our brand opportunities phase next accelerate in very the help stages or growing
else I through authorization, ESG performance. that So top again really bariatric that procedures. other slide to the before medical of starting important our shows that safety, in because top of to XX accounts Slide over it procedures practices endobariatric that is combination XX% respond XXX revisions products bariatric The date is procedure side. durability. the anything the than think of then is point. endoscopic walk combined practices, group with than U.S. Apollo that top And ESGs, it an call one academic then And and starting and of market group And to each of good the balloon XX and up already between endobariatric and results of a clinical XX primarily combination a average let's centers their among has And procedures. year. in accounts importantly XX level with and has average I'm entirely of very this XX them a evidence our in that. do come our delivers No of FDA different are private effectiveness, will year field repeat an private terms that procedures, a is Orbera the in we year-on-year the XXX and on more Slide August the showed including XX makes
of Carolina. pioneering recently new case based X,XXX Atlanta. McGowan live the procedure. a They’ve Dr. ESGs. He adoption a did few opened two And done and leader founder You Dr. gaining presentation weeks And a a initial in Loss. face named in typo. his So these McGowan, in true Weight True is has Chris clearly Dr. of pioneers is accounts. we’re location McGowan who’s ESG physician X,XXX a this North one not the personally years, ago, of That’s In short in
that video hour, ESG. presented they’re intended are – conducting the for and did he answered pardon was challenges excellent. McGowan case Dr. a me. so than social His balanced, lay audience other And about answers platforms, available learning it’s media live while a media YouTube an about social on interested online less flawless and In questions case they a is procedure, in clear, and are ESG more The procedure.
slide. three Some include topics with right body Dr. loss are hand event typically the on – adverse and X.X% can is total in procedure Their safety through same to average return of except XX% of to XX%. I The day are the go profile done return them covered few. a the the to outpatient in and highlight in setting of days. weight patient’s practice all McGowan’s excellent to won’t he is a procedures an rate an of five work average business within
link a more about I or there or like you if know family an encourage to you you’ve ESG who’d And Page look if got XX. interest so to procedure, online. on learning is do colleagues have in friends more the And about or members
is now in endobariatric McGowan specializes gastroenterologist so really who procedures. And Dr. a
describes surgeon XXX at practices surgeons VanderWel the it embrace new found importantly, two patient August of about is really VanderWel Dr. again, who XX and starting he ESG. a the offering outside was two Brandon conference had only And ESG. at consults, Miami bariatric he ESG he was and presented And this the that started was of which of people bariatric he years, big things. Dr. these data also Seattle. experience those presented specifically about are IFSO meeting, addition, out in Slide a that international conference to And In year. in, because heard and in
an patients Almost the him got in of came practice. a ESG The people procedure First could sleeve of two-fold, absolutely his with higher of of about would XXX and that as as and people door reason insurance. more those – those why ESG interested who were expand sleeve. received all, laparoscopic well them laparoscopic treat get help biggest those patients a XXX BMIs
VanderWel’s All pay of procedures. Dr. ESGs are cash
that X:X were people despite procedures. so laparoscopic ratio, from And over ESGs a getting
thing and their is about are their and procedure just can really second do XX% the loss VanderWel’s see XX you he’s that the He Dr. his The outcomes weight outcomes. rigorous body the presentation very and results aftercare up, excellent with follow job was patient an achieving. total team in at months. meaningful in
a my early, This son And really me lot and is in XX. and the the left excuse in and – of very just caught me, discovered that remarkable kind lost a the Carolina familial doing of South patient the is I I come DNA of some is intervene able stories highlight who it’s how a and days to underwent woman well, doing to in it story. family, forward. Page weight, team impact lump understanding an she’s so early so, in actually of our in patient you and on so and ESG very care was procedure medical stories we was drive and a are what drive turned physician. to a these are I’ll from am and and I the were ESG my And starting They very think diagnosed the to a just on one move pretty so because awareness out gratifying see. throat impact cancerous. be in just her patient we in examples emerge. are just see about understanding patient
And marketing this and so patient be patient will we starting adding additional activities actually here quarter. awareness
the get that more so weeks. I adopters And follow the launched are with to mentioned those some as in here endobariatrics. the success absolutely practices having early of coming
is And one for plans endobariatric OverStitch now report are pleased right, similar so and October And we’ve have one them to with training, suturing the of scheduled stage and XXX least this courses completed that course of in about surgeons Most program. – people, physicians. of next obviously our another wave with We’ve already a an at in have already training and I’m importantly, skills next total both in next for have have experienced these group, December a XX year. physicians. interest strong developing got physicians GIs.
outstanding of an faculty. have also We group
Gostout, across Some private includes a already programs Medical Officer, We’ve academic. XX, of Dr. the shown two surgeons, GIs Dr. Dr. the are Ujiki got well the on mix Chief and as of Snow. page, on three practice faculty Page that our and Dr. as members Thaker scheduled Charbel, with Dr. and
practice. And not so aspects possible whole least on the driver gastroplasty of is reimbursement. into but revision And growth also not with course how of on perspectives, sleeve to this outcomes of intragastric and having technical of clinical the best the but and last incorporate procedure, terms balloon in of patient endoscopic the part procedures only range a
with to continue recent the the able FDA are we announcements drive And clearance, to activities critical so and to reimbursement. related
new in Medicare in in for approaches the setting. undergo exploring people and of facility We process how new payment coding are the
advanced We societies are the and new surgical there. with and application around GI a codes both CPT discussions in societies,
materials economic access discussions. coverage engage function really and new the developing we’re discussions to really a to clinical together then And support authorizations. evidence the on payers by putting proposition We’re and reimbursement value case case patient health prior and
both frontline by end the mentioned driver the do of team, to reps has continue as who carry who commercial market the We well year which That previously lines, about to sales as development endobariatric accounts. sales manager with on second of and role end and at our we year. product grow develop. of endobariatric to all target inclusive the the regional focused our helping reps to three are that’s the Our managers grow our new develop XX is growth big be at
our all a sales enhancing we’re than the capabilities, commercial one capabilities, and addition, And in Apollo. build training team, analytics, we sales marketing new U.S. education to our growing still In in sales right? have relatively training, team stronger physician have out less still building organization. half our our importantly, About of organization the medical a year experience at
a so an of delivering team. of some us people And good plus lot here very on become actually from Kirk the it to importer that’s able of hire are the well. we and gotten of out, like have to to at U.S. entire within they’ve net able Medtronic hired our essentially Word not a good team commercial balance and But credit leadership the Sales we’ve excellent some talent. our team. the been and in growth of past and has Ellis, been overhauling Stryker places VP see and to the year, happening And the his and And Scientific things easy XX% people for coming we’ve Boston task over year. while examples are you Apollo last companies
Okay.
and about new product I growth driver, we’re new development, love product our about development. talking next talking So
had Apollo mentioned, including originally. adding that X-Tack been As have the really And into an resources R&D team we outstanding team. R&D developed on folks I our the
renewed out focus this on R&D our is NXT. product called coming new so first of OverStitch And
it’s is are – and either of stronger than channel their new they NXT new catheters, of has It reflection, to that and don’t a control single got it’s scopes, on existing use existing suturing. It’s exist It’s Sx and offers our easier well. tools OverStitch. faster And new how the not product over to install have more – products. on as a so much physicians much with use got increased tissue version allow engage do OverStitch actually single but channels, capabilities product it that focused
professionals the in device our excellent. up so gone setting that the from some has are received been well the feedback allied through in the stages as who are R&D And process. who’ve usability final we the involved we’ve clinicians of health testing often And now with as
We’re do later in things plan testing, a all that final of going year. targeting you’re validations. position the to than and middle be the ready is we’re next development process no product a you goes launch to final towards through launch the to The getting if
has used NXT create market. are that most suturing. to channel single to scopes commonly the for Importantly by the opportunities potential on the multiple access scopes Recall expanded far
And have the that big channel all existing in and adoption the fundamentally enough OverStitch us shift. or scopes, NXT they Sx channel expand not expect make dual satellite existing has opportunities dual help so now that new it to OverStitch primarily is In dual people our scopes the in hospital product both hospitals. to for accounts use channel, them product don’t of have may settings, of a the In and accounts, accounts. we our existing example, dual OverStitch, their many channel of better
to want reasons NXT they’ll So as have well.
Sx then up customers just NXT. have tried who prior previous it’ll And New lot make straight had we to OverStitch struggles product. of a lot of and the with a sense accounts, with start some
as so And an also obvious that’s group to well. tackle
next more So is fourth of it driver the can bringing here essentially on of progress OUS excited then to get And the it follow role second the play year. half in key we actual the terms opportunities. growth we’re there in making very around starting closer NXT market to we’re as the but in and launch, to by
I so wanted first the to And process. provide an update MDR on
you a The has MDR. transition been industry Europe, have the followed in medical quite for about the of I’m those challenging. of So regulations device heard companies sure lot
legacy this quarter. by I’m report for are EU completed to products MDR pleased on Apollo, the having all new very of of anticipate And track our for end and that we so certifications
it’s actually to so me, big addition, lot a David the success team in that. outcome. his have we a credit – a VP accomplishment And navigating of excuse And our and positive in Hooper, Regulatory for and of
These only the the of medical device MDR expect one finalized, do fixation is for page similar are positive some to closure, look has process. all that but a OverStitch. that of see what outcome to maybe the had think you a does on I and still And procedures. being very fact, In stent result endobariatric it new labeling as companies we indications new for defect of
France we terms reimbursement the attention like then and And a products, to that areas X-Tack. and around the like with review for to and more UK be legacy in potentially with being we big places helping our those the in help expect complete on us three the will specific reviewers And marketing in indications we Germany. so are of turn then once our process in
that have through the the year. process X-Tack, we’ll then very first move works, just clearly But outside substantial We get some the made we growth existing first which in And during submission. we products to addition, complete and to way hope next to we’ve got U.S. want opportunities. the half the of
the clinical outside continues out us orders have X-Tack big both year smaller adoption most and feedback, initial markets important, And mentioned, U.S. value we’re now very gotten this both recently to Brazil execution can and recently in ahead but I Brazil. As for there view Australia. plan nine in X-Tack markets And economic which that we very we’ve our good earlier very outside of in U.S. some the mostly in cleared in and are of and the markets, reinforce
targeting mark. XXXX we’re other X-Tack and CE follows a the countries launch of CE in I Europe And so, just that countries in as mark mentioned,
than Canada. more other outside Canada, opportunities. have the Some given presence we of a in ironically, small U.S., our XX% that businesses
in starting opportunity. that half so And really is that we’re another looking to Japan the and first new OverStitch next for change of we’re with clearances year. X-Tack for working exciting
And cases the this China develop to the a We start the our market. essentially you last in earlier weeks Marketing Hunan China in already ESGs in And They’ve in and our data, for announced China, International an already year then Sales and just port, back there. the into clearance initial got in experience And incredibly as previously gives Mike in a came that have market. VP opportunities Taiwan, have completed already two Gutteridge, we to we’ve about collecting collecting OverStitch X-Tack medical Japan trade excited in both Chinese we including over in XXXX. clearance first province. which free was and foothold of then Japan and continue
some presence who have and also ESGs are with investigators with population. XX% Taiwan body emerging already We loss data excellent publishing total in with clinicians an Asian an in weight
things, So clearances and clear the going additional Mainland can important and a data very into years. for of China, we to help the over two is the those think be way combination coming foothold
about a these a really this of I’m catalysts summary, the to in and Page year So as systems. of One forward. drive cadence area got exciting call a the over about haven’t talked We’ve page. forward I each half XX. continue new is year, to next, yet look that and REVISE to on shown And highlight ESG on
of be some a a in XX% the doing We consistent in targeted in a very launch of phase select move $XX which are gives XX%. half the all QX throughout. communicated about apply the we guidance grower we’re that And further our then that the nearly have accelerate us to this elements limited growth growth here year. what years of reiterating on a a of in strategy. cadence and in especially finally, summarize, pleased first those of And furthermore, confidence results launch operational to to increased previously, you next opportunities we the on can track plus to talked expand of we’ll and ahead, the here the as with $XX this then see our be then belief of to basically other manufacturing And million just launch full the And to we That U.S. we I’ve position complete quarter. call involves into in million, accounts. finalizing a
And so the to John, up open let’s questions. call with that,
